Learn more about the efficacy of switching to doravirine/islatravir despite baseline resistance in proviral DNA, how immunocompromised individuals hospitalized with COVID-19 remain at increased mortality risk and other research ready to inform clinical ...

AbstractBackground. Gram-negative bacterial bloodstream infections (BSI) cause substantial mortality and morbidity. The GAME CHANGER trial compared cefider

A phase III clinical trial evaluated Silevimig, a bispecific anti-rabies monoclonal antibody targeting antigenic sites I and III, as a substitute for human